BTOG 2019 | MARS 2 trial: radical surgery for mesothelioma

Name: MARS 2 trial: radical surgery for mesothelioma
Uploaded: 2019-01-24T00:00:00Z
Duration: 1 min 7 s
Description: Eric Lim, MD, of the Royal Brompton & Harefield NHS Foundation Trust, London, UK, discusses the Mesothelioma and Radical Surgery 2 (MARS 2; NCT02040272) trial, which is investigating whether pleurectomy/decortication confers a survival advantage. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.

Eric Lim • 24 Jan 2019

BTOG 2019

Mesothelioma

MARS 2 MesoVATS

Eric Lim, MD, of the Royal Brompton & Harefield NHS Foundation Trust, London, UK, discusses the Mesothelioma and Radical Surgery 2 (MARS 2; NCT02040272) trial, which is investigating whether pleurectomy/decortication confers a survival advantage. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.